Payment overview · 2025
General Payments
$402.34
19 reported records · 9 companies
Healthcare provider profile · identity verified
Naveed Siddique, MD
Allopathic & Osteopathic Physicians|Family Medicine · WARREN, MI · NPI 1831282706
Verified facts
What the public records show
CMS Open Payments records show Naveed Siddique, MD received $402.34 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Xifaxan.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 447 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.31 | 23.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.26 | 18.7% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.17 | 13.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.10 | 12.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.76 | 8.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.04 | 7.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.33 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.24 | 6.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.13 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $402.34 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.31 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.26 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.26 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.17 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.10 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 447 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
447 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1602 | 233 |
| Metformin Hcl | Metformin Hcl | 1311 | 186 |
| Omeprazole | Omeprazole | 1128 | 165 |
| Lisinopril | Lisinopril | 1058 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 1005 | 145 |
| Simvastatin | Simvastatin | 942 | 123 |
| Losartan Potassium | Losartan Potassium | 598 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 535 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 477 | 72 |
| Diclofenac Sodium | Diclofenac Sodium | 470 | 134 |
| Jardiance | Empagliflozin | 447 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 357 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 52 |
| Azithromycin | Azithromycin | 336 | 228 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 55 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 307 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 307 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 306 | 44 |
| Atenolol | Atenolol | 305 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 56 |
| Carvedilol | Carvedilol | 273 | 41 |
| Famotidine | Famotidine | 269 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 268 | 74 |
| Gemfibrozil | Gemfibrozil | 258 | 29 |
| Montelukast Sodium | Montelukast Sodium | 229 | 33 |
| Ibuprofen | Ibuprofen | 226 | 84 |
| Furosemide | Furosemide | 224 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 221 | 34 |
| Glipizide | Glipizide | 205 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 205 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 42 |
| Tradjenta | Linagliptin | 194 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 176 | 26 |
| Glipizide Er | Glipizide | 175 | 22 |
| Eliquis | Apixaban | 173 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 171 | 22 |
| Linzess | Linaclotide | 163 | 20 |
| Januvia | Sitagliptin Phosphate | 152 | 17 |
| Glimepiride | Glimepiride | 148 | 20 |
| Farxiga | Dapagliflozin Propanediol | 145 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 142 | 29 |
| Nifedipine Er | Nifedipine | 141 | 26 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 140 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 23 |
| Allopurinol | Allopurinol | 131 | 21 |
| Ketoconazole | Ketoconazole | 128 | 21 |
| Promethazine Hcl | Promethazine Hcl | 127 | 94 |
| Hydrocortisone | Hydrocortisone | 126 | 48 |
| Amoxicillin | Amoxicillin | 125 | 89 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 120 | 38 |
| Vascepa | Icosapent Ethyl | 119 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 118 | 18 |
| Sertraline Hcl | Sertraline Hcl | 118 | 13 |
| Naproxen | Naproxen | 117 | 43 |
| Potassium Chloride | Potassium Chloride | 117 | 18 |
| Trulicity | Dulaglutide | 112 | 15 |
| Meclizine Hcl | Meclizine Hcl | 111 | 51 |
| Ozempic | Semaglutide | 110 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 18 |
| Celecoxib | Celecoxib | 95 | 18 |
| Ezetimibe | Ezetimibe | 94 | 16 |
| Trazodone Hcl | Trazodone Hcl | 93 | 16 |
| Alendronate Sodium | Alendronate Sodium | 84 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 81 | 16 |
| Gabapentin | Gabapentin | 81 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 78 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 48 |
| Procto-Med Hc | Hydrocortisone | 75 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 73 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 61 |
| Donepezil Hcl | Donepezil Hcl | 70 | suppressed |
| Nitroglycerin | Nitroglycerin | 70 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 58 |
| Fenofibrate | Fenofibrate | 66 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | suppressed |
| Methylprednisolone | Methylprednisolone | 59 | 51 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 58 | 16 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 57 | 11 |
| Enalapril Maleate | Enalapril Maleate | 56 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 39 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 54 | 22 |
| Colchicine | Colchicine | 51 | suppressed |
| Lidocaine | Lidocaine | 51 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | suppressed |
| Nystatin | Nystatin | 48 | 23 |
| Meloxicam | Meloxicam | 47 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 14 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 46 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 35 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 42 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 13 |
| Loperamide | Loperamide Hcl | 40 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 14 |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Betamethasone Valerate | Betamethasone Valerate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 23 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 22 | 19 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Valsartan | Valsartan | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Prednisone | Prednisone | 16 | 15 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 13 |
| Metolazone | Metolazone | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $402.34 · 19 records | Novo Nordisk Inc | Cologuard Collection Kit, IBSRELA, JARDIANCE, Korlym, OTEZLA, Ozempic, REPATHA, Rybelsus, VERQUVO, XIFAXAN, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error